NeuroBo Pharmaceuticals Stock Forum

$NeuroBo Pharmaceuticals(NRBO.US)$
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has dosed the first patient in Part 2 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for obesity treatment. This MAD study, expected to enroll 36 participants, will investigate safety, tolerability, and pharmacokinetics, with top-line data anticipated...

$NeuroBo Pharmaceuticals(NRBO.US)$  Top-Line Data Readout From Single Ascending Dose Part 1 Expected in Q3 2024 & From Multiple Ascending Dose Part 2 in Q1 2025

$NeuroBo Pharmaceuticals(NRBO.US)$
NeuroBo Pharmaceuticals Announces the CLOSING of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$NeuroBo Pharmaceuticals(NRBO.US)$ Dong-A ST (10%+) Buys 2.54M Shares of NeuroBo Pharmaceuticals at Avg Price of $3.13; Total Value Of $7,964,378.9

$NeuroBo Pharmaceuticals(NRBO.US)$
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$NeuroBo Pharmaceuticals(NRBO.US)$
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
NeuroBo Pharmaceuticals revealed pre-clinical data for DA-1726, a new dual oxyntomodulin analog agonist, showing superior weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide. In obese mouse models, DA-1726 significantly outperformed survodutide ...

Here are the levels to keep on watch.
Larger Image: tradingview.com...
$NeuroBo Pharmaceuticals(NRBO.US)$

$NeuroBo Pharmaceuticals(NRBO.US)$
NEWS
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June